A randomized phase II study of vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX in patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led study

被引：19

作者：

Cohen, Deirdre Jill

Christos, Paul J.

Sparano, Joseph A.

Kindler, Hedy Lee

Catenacci, Daniel Virgil Thomas

Bekaii-Saab, Tanios B.

Tahiri, Sanaa

Janjigian, Yelena Yuriy

Gibson, Michael K.

Chan, Emily

Rajdev, Lakshmi

Urba, Susan

Wade, James Lloyd

Kozuch, Peter

Love, Erica

Vandris, Katherine

Takebe, Naoko

Hochster, Howard S.

机构：

[1] NYU, Inst Canc, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Montefiore Med Ctr, Albert Einstein Coll Med, New York, NY USA

[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[5] Univ Chicago, Chicago, IL 60637 USA

[6] Ohio State Univ Hosp, Columbus, OH 43210 USA

[7] Ohio State Univ, Columbus, OH 43210 USA

[8] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[9] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[11] Montefiore Med Ctr, Bronx, NY 10467 USA

[12] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA

[13] Decatur Mem Hosp Canc Care Inst, Decatur, IL USA

[14] Beth Israel Deaconess Med Ctr, Continuum Canc Ctr, New York, NY 10003 USA

[15] Invest Drug Branch, Canc Therapy Evaluat Program, Rockville, MD USA

[16] Yale Univ, Sch Med, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.67

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1